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Abstract of the thesis of  
Steven D. Ebers  
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THE EFFECT OF TESTOSTERONE ON LEYDIG CELL DEVELOPMENT IN MALE 
YHR+ MICE 
 
Mentor: Dr. Prema Narayan 
 
Leydig cells (LC) are specialized cells in the testis that develop during puberty 
and are responsible for producing testosterone. Luteinizing Hormone (LH) and 
testosterone are important for LC development.  Binding of LH to its receptor (LHR) 
initiates the production of testosterone.  Constitutively active mutations in LHR have 
been identified in humans resulting in puberty in males as young as 3 or 4 years of age.  
A transgenic mouse (YHR+), was generated which mimics the constitutively active LHR 
by fusing the hormone, human chorionic gonadotropin, to LHR to continually activate the 
receptor.  Testosterone levels in YHR+ mice are high at neonatal ages.  Previous studies 
in the lab have shown that YHR+ mice have decreased LC numbers compared to wild 
type (WT) mice.  It was hypothesized that high levels of testosterone at neonatal ages was 
responsible for the decrease in LC numbers and was causing a decrease in the 
proliferation of LCs.  To test this hypothesis, the action of testosterone was blocked with 
the androgen antagonist, flutamide, and the total number of LCs as well as the number of 
proliferating LCs were determined.  There was no significant increase in LC number or in 
proliferation of flutamide treated YHR+ mice suggesting that other factors may be 
involved in the decrease in LC number.    Together, these results suggest that high 
neonatal testosterone is not sufficient to inhibit LC development.  
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Introduction 
 
Gonadotropins 
 
The gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) are 
secreted from the anterior lobe of the pituitary gland at puberty.  After being released by 
the pituitary gland, the hormones have influence upon the male and female gonads (1).  
In males, binding of LH to its receptors, expressed in the Leydig cells within the testes is 
required for testosterone production.  Testosterone along with FSH stimulation of the 
Sertoli cells is essential for sperm production and maturation (Fig. 1).  Leydig cells, 
found in the interstitium of the testis are specialized cells that develop during puberty and 
start as progenitor Leydig cells (PLC) at 10 days of age in the mouse.  These cells 
proliferate and differentiate into immature Leydig cells (ILC) at about 35 days of age, 
and adult Leydig cells (ALC) at about 56 days of age (Fig. 2).  PLCs are spindle shaped 
and are found close to the seminiferous tubule.  PLCs develop into ILCs, which move 
away from the seminiferous tubule.  As it develops it acquires more smooth endoplasmic 
reticulum as well as cytoplasmic lipid droplets which both act to maintain the integrity of 
the cell and cause it to become more round shaped.  ALCs, the largest of the Leydig cells 
are round because of their high smooth endoplasmic reticulum content although they 
contain no cytoplasmic lipid droplets.  ALCs are responsible for the production of 
testosterone (2,3).  Without the production of testosterone, these mice would be 
incompetent in producing offspring.  The hormones LH, FSH, and testosterone are 
important for Leydig cell development.  
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The Yoked Hormone Receptor Transgenic Mouse (YHR+) 
 
In humans, a mutation can occur that causes the LH receptor to be constitutively active, 
even in the absence of LH.  This causes testosterone to be produced even before puberty.  
This mutation can lead to a male reaching puberty at an age as young as 3 or 4 years.  A 
transgenic mouse, called the YHR+ mouse, was generated which mimics the 
constitutively active LH receptor by using the hormone, human chorionic gonadotropin 
(hCG) to continually activate the LH receptor and cause precocious puberty to occur (4) 
(Fig. 3).  hCG is homologous to LH and can bind to the LH receptor to activate it.  
Previous studies in the lab have shown that these mice exhibit high levels of testosterone 
as early as 10 days of age but a low number of Leydig cells compared to wild type (WT) 
mice (Fig. 4). This reduction in the number of Leydig cells is due to a decrease in 
proliferation of PLCs at 10 days and 2 weeks of age. This YHR+ mouse provides a model 
to study the hormonal regulation of Leydig cell development. In WT mice, a significant 
testosterone increase occurs at 5 weeks, whereas in the YHR+ mouse, the increase occurs 
at 10 days. It is hypothesized that the high levels of testosterone at an inappropriate time 
causes a decrease in Leydig cell number.  In this study, I have tested this hypothesis by 
blocking the action of testosterone with the androgen receptor antagonist, flutamide and 
determining its effect on Leydig cell numbers and proliferation. 
 
 
 
  
 
 
 
 
Figure 1.  Gonadotropin-releasing
and acts upon the pituitary which releases luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) which act 
respectively.  Testosterone is then released from Leydig cells and stimulates the Sertoli 
cells along with FSH to aid in sperm production and maturation.
negative feedback on the pituitary and
-hormone (GnRH) is secreted from the hypothalamus 
upon the Leydig cells and Sertoli cells, 
  Testosterone exhibits 
 the hypothalamus.  
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Figure 2.  Leydig cell development
Step 1 represents the progression from PLC to ILC while step 2 represents the 
progression of ILC into ALC.  PLCs are spindle shaped and become rounded as they 
progress into ILCs.  ILCs and 
morphologically.  Adapted from Benton et al. (3).
 
 
 
.   
ALCs are both round and cannot be distinguished 
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Figure 3.  Schematic illustration of the yoked hormone receptor (YHR).
Human chorionic gonadotropin (hCG) fused to the luteinizing hormone receptor
(LHR) activates it continuously.
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Figure 4.  A decrease in Leydig cell number is seen in YHR+ mice at 5, 8 and 12 
weeks of age (n=5).  Data from Coonce et al. (5). 
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Goals of the Study 
 
1.) To block the action of testosterone with the androgen receptor antagonist, 
flutamide and determine its effect on Leydig cell numbers. 
YHR+ were previously found to express high levels of testosterone beginning at 10 days 
of age whereas WT mice exhibit a similar increase at 5 weeks of age.  These YHR+ mice 
also have been found to have a lower number of LC than the WT mice.  In order to 
determine whether this high level of testosterone at neonatal ages in the YHR+ mice is the 
cause of the low number of LC, testosterone action was blocked with the androgen 
receptor antagonist, flutamide, to examine its effects on LC numbers. 
 
2.) To analyze the number of proliferating Leydig cells in the YHR+ vehicle and 
flutamide treated animals to determine whether testosterone plays a role in 
proliferation. 
YHR+ mice exhibit high levels of neonatal testosterone and a low number of Leydig 
cells.  To determine whether the high levels of testosterone at this inappropriate time is 
causing a decrease in LC proliferation, YHR+ mice who had been treated with androgen 
antagonist were compared to control YHR+ mice and the percent of proliferating LC were 
determined for each group. 
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Experimental Methods 
 
Animal care and treatment 
All animal studies were approved by the Institutional Animal Care and Use Committee at 
SIU.  Mice were maintained in a conventional colony with a 12h light, 12h dark cycle 
and fed a standard laboratory chow and tap water ad libitum. Mice were euthanized by 
CO2 asphyxiation and tissues were harvested.  
 
Treatment of YHR+ mice with flutamide and vehicle control 
 In effort to determine whether blocking the action of testosterone with flutamide will 
increase the number of Leydig cells, it was first necessary to determine the optimal dose 
of flutamide that was effective in blocking the action of testosterone.  To do this, 
50µg/animal·day of flutamide was injected subcutaneously above the shoulders into male 
YHR+ mice on day 7, 8 and 9 to ensure the blockage of testosterone before the time 
period of PLC proliferation.  This dose was chosen based on a previous study (6).  The 
mice were dissected on day 10 and the effectiveness of the dose was determined by 
weighing the seminal vesicles.  The YHR+ mice were injected subcutaneously above the 
shoulders from day 7 through day 14 with 50µg/animal·day of flutamide.  Another set of 
YHR+ mice were treated with the vehicle control (sesame oil).  The treatments occurred 
at these ages because Leydig cells begin to develop around day 10 and testosterone 
increased in YHR+ mice at day 10.  
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 Experimental Setup: 
 YHR+ mice were treated with vehicle and flutamide starting at 7 days of age and were 
dissected on day 10, weeks 2, 3, 5, and 8 and their testes were collected.  The testes were 
fixed in Bouin’s solution, embedded in paraffin, and serial sections (5 µm) were obtained 
where sections on each slide were 25 µm apart.  The sections were then stained using an 
antibody specific for 3β hydroxysteroid dehydrogenase 1 (3βHSD1), which is specific for 
Leydig cells.  Blocking of endogenous peroxidase was done by using 3% hydrogen 
peroxide in methanol for 30 min.  The sections were then incubated with normal goat 
blocking serum over night.   The sections were then incubated with the primary antibody 
against 3βHSD1 at a dilution of 1:4000 for 1 h.  Sections were then incubated in 
biotinylated secondary antibody for 10 min.  Vectastain® Elite ABC reagent was then 
used to incubate the sections for 10 min followed by diaminobenzidine which is used to 
visualize the antibody-antigen complexes that had formed.  Hematoxylin was then used 
to counterstain the sections (Fig. 5). 
  
Quantification of Leydig cells: 
 5 areas in different parts of each section on each slide were randomly chosen and 
photographed at a magnification of 400X (Fig. 6). Only the Leydig cells that were stained 
with 3βHSD1 were counted within each area.  Leydig cells were counted in sections that 
were 5µm in depth and were 25µm apart.  To determine the number of Leydig cells per 
testis, the weight of the testis was used as an approximation of the testis volume because 
the density of the testis is approximately 1mg/ml (7).  The weight was multiplied by the 
quotient of the total number of Leydig cells counted in a defined volume of 0.0047mm3.   
 This volume was calculated by multiplying th
section (5 µm), and multiplying this number by the total number of boxes that were 
counted per testis.   
 
 
Quantification of Proliferating Leydig cells
YHR+ mice were injected from 7
50µg/animal·day of flutamide
intraperitoneally, 2h prior to sacrifice at day 14.  Testes were fixed
embedded and serial sectioned
antibodies against BrdU to mark the proliferating cells and 3
cells.  Endogenous peroxidase was blocked by incubating slides in 3% hydrogen peroxide 
for 30 min.  Sections were then incubated in normal goat serum for 1 
incubated over night in the primary antibody against 
Sections were then incubated in biotinylated secondary antibody for 1 h followed by 
incubation in streptavidin 594 in a 1:200 dilution for 30 min.  The sectio
incubated in Vector® M.O.M.™ Mouse Ig Blocking Reagent for 3 h followed by 
incubation with a primary antibody against BrdU in a 1:100 dilution for 1 h.  The sections 
were then incubated in the secondary antibody against DK
1 h.  The slide was then mounted with a mounting medium with dapi.  
BrdU and 3βHSD1 positive cells was 
number of 3βHSD1 positive LCs. 
e area of the box by the thickness of the 
 
-13 days of age with either vehicle control or 
 subcutaneously and with bromodeoxyuridine (BrdU)
 in bouins solution
 (5 µm). Immunofluorescence staining was performed with 
βHSD1 to mark Leydig 
h and then were 
3βHSD1 in a 1:4000 dilution. 
ns were then 
αms 488 in a 1:200 di
The number of 
quantified and expressed as a percent of the total 
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 Figure 5.  Experimental Setup
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 Figure 6.  Sections of testis were stained with an antibody specific for 3
Leydig cells. 
 A.   Whole testis section with boxes representing areas of counted Leydig cells.  
 B.   Higher magnification at 400x of a representative box showing PLC and ALC.
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Results and Discussion 
 
The weight of the seminal vesicles of the YHR+ mice, which have been treated with 
flutamide were compared to the weight of the seminal vesicles from WT mice and YHR+ 
mice that have been treated with only vehicle.  Because the seminal vesicles respond to 
androgens and become larger in the presence of testosterone, if the action of testosterone 
is blocked effectively, the weight of the YHR+ seminal vesicles treated with flutamide 
should be similar to those of the WT mice.  The weight of the seminal vesicles indicated 
that testosterone was blocked effectively at 2 and 3 weeks of age (Fig. 7).  At both 2 and 
3 weeks of age, the weight of the flutamide treated YHR+ mice was significantly lower 
than the vehicle YHR+ mice and was comparable to the seminal vesicle weight of the WT 
mice at 3 weeks.  This suggests that the effect of testosterone was effectively blocked at 
these ages.  By 5 weeks there was no significant difference in the weight of the seminal 
vesicles in the vehicle WT, vehicle YHR+ and flutamide treated YHR+ mice.  This 
suggests that the effect of the androgen antagonist flutamide had worn off and 
testosterone was able to exert its normal effects by this age.  This increase in testosterone 
effects at 5 weeks is desired because in the WT mouse a large increase of testosterone is 
seen at 5 weeks and is considered normal.   
After quantification of LCs at 2, 3, 5 and 8 weeks of age, no significant difference 
in the number of LCs was seen at 2 or 3 weeks of age (Fig. 8).  The number of LC was 
not significantly altered in the flutamide treated YHR+ mice compared to vehicle treated 
YHR+ mice.  This suggests that high levels of testosterone at neonatal ages are not 
sufficient to inhibit the development of LC.   However the general trend is that the 
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number of LC in the flutamide treated YHR+ mice is higher than that of the vehicle 
YHR+ mice although not significantly higher.  This suggests that testosterone may play a 
role in the development of LCs along with other factors. 
No significant difference was found when comparing the flutamide treated YHR+ 
mice to the vehicle treated YHR+ mice at 2 weeks of age.  This data suggests that the 
high levels of neonatal testosterone did not cause a decrease in LC proliferation (Fig. 9).  
Other factors may be involved in the proliferation of LC in addition to testosterone.  
Further study is needed to determine which factors are contributing to LC 
development and proliferation in the YHR+ mice.  It has been found that FSH levels are 
significantly lower in YHR+ mice compared to WT mice (4).  FSH could be a 
contributing factor to the low numbers of LC seen in YHR+ mice and should be studied to 
determine this.  Another possible factor contributing to the difference in LC number 
could be IGF-1.  IGF-1 is important for LC development and when suppressed, results in 
reduced numbers of LC (8).  Testosterone is known to increase IGF-1 (9).  Therefore, 
because we are blocking the action of testosterone in the flutamide treated YHR+ mice, 
IGF-1 levels are likely to be decreased which could combat the expected increase in LC 
numbers.  Because it is not known whether or not IGF-1 levels are altered in the YHR+ 
mice, it would beneficial to determine IGF-1 levels the future. 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 7.  Data represent mean ± SEM (n=5) and were analyzed by one
Different letters indicate significant differences between treatment groups (p<0.0
-way ANOVA. 
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5). 
 Figure 8.  Data are expressed as mean ± SEM and were analyzed by 
(n=5).  Different letter assignments indicate significant di
(p<0.05)  
 
one-way ANOVA 
fference in treatment groups. 
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Figure 9.  Data are expressed as mean ± SEM and were analyzed by t test (n=4-5).  
Different letter assignments indicate significant difference in treatment groups. (p<0.05)  
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